-
Clin Toxicol (Phila) · Jul 2013
Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series.
- Simon L Hill, Tom Doris, Shiv Gurung, Stephen Katebe, Alexander Lomas, Mick Dunn, Peter Blain, and Simon H L Thomas.
- Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, UK. simon.hill@ncl.ac.uk
- Clin Toxicol (Phila). 2013 Jul 1;51(6):487-92.
Context4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is a N-methoxybenzyl-substituted phenethylamine with potent serotoninergic effects. We describe seven cases of analytically confirmed toxicity due to the recreational use of 25I-NBOMe in the United Kingdom.Case SeriesSeven patients, all young adult males, presented to hospitals in the northeast of England with clinical toxicity after recreational drug use in January 2013. Clinical features included tachycardia (n = 7), hypertension (4), agitation (6), aggression, visual and auditory hallucinations (6), seizures (3), hyperpyrexia (3), clonus (2), elevated white cell count (2), elevated creatine kinase (7), metabolic acidosis (3), and acute kidney injury (1). LC-MS/MS analysis identified 25I-NBOMe as the main active substance in the plasma of all seven cases.ConclusionsSevere clinical toxicity may occur following recreational use of 25I-NBOMe, with stimulant and serotoninergic features predominating. Clinicians should be alert to this substance, in view of its emergence in Europe as well as in the United States.
Notes